生物制剂治疗成人炎症性肠病:合理选择和转换  

Biologics for the treatment of inflammatory bowel disease in adults:options and switches

作　　者：胡品津[1] Hu Pinjin(Department of Gastroenterology,the Sixth Affiliated Hospital,Sun Yat-sen University,Guangzhou 510655,China)

机构地区：[1]中山大学附属第六医院消化内科,广州510655

出　　处：《中华炎性肠病杂志（中英文）》2022年第2期97-105,共9页Chinese Journal of Inflammatory Bowel Diseases

摘　　要：多种生物制剂已被批准用于治疗炎症性肠病(IBD)。但由于缺乏比较生物制剂间疗效和安全性的头对头的随机对照研究, 以及缺乏准确预测生物制剂疗效的方法, 临床医生常存在如何选择生物制剂的困惑。本文参考目前已有的临床研究证据, 再结合国际主流意见和我国的应用经验, 提出IBD治疗过程中生物制剂选择和转换的建议, 供同行参考。Many biologics have been approved for the treatment of inflammatory bowel disease(IBD).However,due to the lack of head-to-head randomized controlled studies comparing the efficacy and safety of biologics,and the lack of methods to accurately predict the efficacy of biologics,clinicians are often confused about how to select biologics.In this paper,based on the existing clinical evidence,combined with the international mainstream opinion and the application experience of China,suggestions on the options and switches of biologics in the treatment of IBD are put forward for the reference of clinicians.

关 键 词：生物制剂 炎症性肠病 英夫利西单克隆抗体 阿达木单克隆抗体 维得利珠单克隆抗体 乌司奴单克隆抗体 选择 转换 

分 类 号：R574[医药卫生—消化系统]